CellCept (mycophenolate mofetil) is associate degree immunosuppressive drug, a drugs that lowers your body’ssystem. The system helps your body fight infections. Your body might “reject” associate degree surgery once thesystem treats the new organ as associate degree trespasser. associate degree immunosuppressive drug helps to forestall this rejection.
CellCept is employed to forestall your body from rejecting a urinary organ, liver, or heart transplant. CellCept is typically given with cyclosporine (Sandimmune, Neoral) and a steroid medication.
Submit your review
Get emergency medical help if you have any of these signs of an allergic reaction to this medication: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
CellCept can lower blood cells that help your body fight infection. This can lead to serious conditions including herpes, shingles, hepatitis, blood or tissue infections, severe brain infection causing disability or death, or a viral infection causing kidney transplant failure. Call your doctor right away if you have:
diarrhea, stomach pain, nausea, vomiting, weight loss;
weakness on one side of your body, loss of muscle control;
confusion, thinking problems, loss of interest in things that normally interest you;
fever, night sweats, tiredness, painful mouth sores, flu symptoms;
runny or stuffy nose, cough, sore throat, ear pain, headache;
pale skin, feeling light-headed or short of breath, easy bruising or bleeding (nosebleeds, bleeding gums);
bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
pain or burning when you urinate;
swelling, warmth, redness, or oozing around a skin wound; or
a new bump or lesion on your skin, or a mole that has changed in size or color.
Common CellCept side effects may include:
nausea, vomiting, diarrhea;
swelling in your ankles or feet; or
high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, shortness of breath).
Adults A dose of 1 g administered orally or intravenously (over NO LESS THAN 2 HOURS) twice a day (daily dose of 2 g) is recommended for use in renal transplant patients. Although a dose of 1.5 g administered twice daily (daily dose of 3 g) was used in clinical trials and was shown to be safe and effective, no efficacy advantage could be established for renal transplant patients. Patients receiving 2 g/day of CellCept demonstrated an overall better safety profile than did patients receiving 3 g/day of CellCept. Pediatrics (3 months to 18 years of age) The recommended dose of CellCept oral suspension is 600 mg/m2 administered twice daily (up to a maximum daily dose of 2 g/10 mL oral suspension). Patients with a body surface area of 1.25 m2 to 1.5 m2 may be dosed with CellCept capsules at a dose of 750 mg twice daily (1.5 g daily dose). Patients with a body surface area >1.5 m2 may be dosed with CellCept capsules or tablets at a dose of 1 g twice daily (2 g daily dose).